FCGR1A and cholangiocarcinoma: (127) found that CD247, FCGR1A and TRRAP were potential antigens of mRNA vaccines against cholangiocarcinoma, especially for patients with the immune subtypes 2 (IS2) tumors, providing a theoretical foundation for the development of anti-cholangiocarcinoma mRNA vaccines and identifying suitable vaccination targets.